|
|
 |
|
Viewing report
|
|
|
|
SPECIAL REPORT: 2007 Industry Dynamics-Lessons Learned
Decision Resources, Inc., Dec 2007, Pages: 39
Introduction
Moderate successes and “business as usual” characterize the performance of the pharmaceutical industry in 2007. In this year-end retrospective report, we contemplate the importance of key events and achievements in the industry. We asked industry-leading experts to identify particularly noteworthy events in 2007 and lessons that can be learned for 2008. Six themes emerged; our experts discuss their implications for the industry. Furthermore, we offer a Spectrum Scorecard that assesses industry performance in a variety of critical areas.
Get the Answers You Need to Shape Your Strategy
- The pharmaceutical industry may never be to return to its glory days, but it can exert control over its future through the strategies and changes that it is willing to adopt today. What strategic options are essential to achieve success in today’s evolving markets? What are the future implications of these changes for pharmaceutical companies?
- Pharmaceutical companies must ensure they are “fit for purpose” in today’s business environment. What strategies can pharmaceutical management pursue to capture and harness the essence of a result oriented business and make their companies truly fit for purpose? How can they uncover previously unrealizable profits and growth and also differentiate themselves so that they can grasp valuable competitive advantage?
Scope
- 2007 in review: a retrospective on news and key themes from the year.
- Seeking a new vision for the pharmaceutical industry: looking for the Holy Grail of opportunity.
- Negative industry impacts: from generics erosion, biogenerics, declining productivity, and drug safety
- concerns combined with the increased importance of specialty pharma and biotech.
- New strategies needed for future success: rethinking the blockbuster strategy, a holistic approach to
- management style, fit with strategy, choosing strategies and opportunities wisely.
- Jumping on technology opportunities: identifying key technologies and turning innovation into
- new products and services.
- New value propositions: value-for-money.
- Growing influence of U.S. states: legislative bills, litigation by state attorneys general, lessons
- learned.
- 2007 industry report card: how successful was Big Pharma in capitalizing on the many
- opportunities available in 2007?
List of Key Concepts/Opportunities:
- Best in Class
- Biogenerics/biosimilars
- Biologics
- Biomarker-driven
- Black box warnings
- Blockbuster business model
- Choosing wisely
- Clinical trial registries
- Consolidation
- Consumerism
- Cost/price battle
- Cost-cutting
- Critical success factor (CSF)
- Disruptive technology
- Downsizing
- Drug safety
- First-in-class
- Fit for purpose
- Flexibility
- Flight-of-capital
- Focused strategies
- Free-market economies
- Fully integrated pharmaceutical company (FIPCO)
- Generics erosion
- Globalization
- Growth deceleration
- Holistic approach
- Inlicensing
- Innovation
- Life-cycle management
- Litigation proceedings
- Little Science
- Low-hanging fruit
- Management style
- Managing Risk
- Margins
- Merger & acquisition (M&A)
- Me-too products
- Money-back guarantee
- Monoclonal antibodies
- New chemical entity (NCE)
- New molecular entity (NME)
- Not-invented-here syndrome
- Organizational uncertainty
- Patent expiry
- Personalized medicine
- Pharmacogenomics
- Premium pricing
- Product acquisition
- Protein optimization
- R&D productivity
- Reactive strategies
- Reference pricing
- Resource allocation
- Results-oriented business
- Return on investment (ROI)
- Revolutionary transformation
- Risk averse
- Risk sharing
- RNA interference
- Rx dilemma
- Second-generation products
- Specialty pharma
- State attorneys general
- Stem cells
- Strategic choice
- Targeted therapy
- Technology opportunities
- Transparency
- Unmet need
- Value-added advantage
- Value propositions
- Value-for-money
Customers who bought this item also bought
SPECIAL REPORT: Lessons Learned in the Pharma Industry, 2008
Special Report: Successes and Lessons Learned in the Pharmaceutical Industry, 2009
Pharma's Changing Business Strategies: Five Deadly Pharma Sins
State of the Pharmaceutical Industry, 2008
State of the Pharmaceutical Industry, 2007
Special Report: State of the Pharmaceutical Industry, 2009
Kick-Starting R&D in India: Challenges and Opportunities
Big Pharma’s New Licensing Strategies
China: The Key Pharmemerging Market - Deciphering Major Pharma Companies’ China Strategy
The New Trends of Global Pharmaceutical Outsourcing: New Developments in Strategy, Market, Service and Technology
|
|
|
|
